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Conclusions: SBRT of apically located lung lesions may cause 
severe neurological symptoms; Dmax and large PTV being risk 
factors. 
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Purpose/Objective: To determine if a weekly cone-beam CT 
(CBCT) is enough to evaluate the entire tumor inclusion and 
the reproducibility throughout the radiation course treatment 
in lung cancer. 
Materials and Methods: Thirty-six lung cancer patients were 
treated with image-guided radiotherapy (IGRT) on an Elekta 
Synergy Beam Modulator linear accelerator.  
The GTV included the tumor and the positive nodes in PET-CT 
and pathologic analysis. The PTV was configured with the 
GTV and a margin of 0.7 cm – 1 cm in all directions. 
In our protocol of lung cancer treatment, prior to each 
radiotherapy fraction we make one cone-beam CT every day 
on the first five days of treatment using automated soft-
tissue registration. The positional errors of the reference 
image in relation to the acquired image (given in terms of 
translation movements) were obtained. No rotations were 
permitted. The average of these translational movements in 
the three axes (x, y, z) was calculated. This average was 
applied from the sixth day of treatment until the end. 
Weekly image guidance was registered resulting in at least 10 
CBCT scans for each patient. The deviations in the three axes 
in every weekly CBCT with respect to the average were 
analyzed (Tx, Ty, Tz) 
Results: The graphics summarize the result of our analysis.  
 
 
In 29 patients (80.6%) the mean value of the difference 
between the positional errors compared to the average was: 
x = (0.19 ± 0.14) cm, y = (0.21 ± 0.14) cm, z = (0.27 ± 0.16) 
cm. All these values were less than 0.5cm and were 
considered correct for the suitable treatment of the patients. 
The shifts in the z axis showed more variability compared to 
the other axes mainly related to breathing movements. 
Nevertheless this z axis variability did not influence on the 
entire tumor inclusion and the set up reproducibility. 
In the other 7 patients (19.4%) we obtained a greater 
difference in either axes, and a CBCT more often than once a 
week was evaluated by the physician. 
Conclusions: Our preliminary results showed that in most 
lung cancer patients treated with IGRT, once an average is 
calculated after the first five days of treatment, a weekly 
cone-beam CT is enough to evaluate the entire tumor 
inclusion and the reproducibility throughout the radiation 
treatment.  
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Purpose/Objective: Lung cancer is responsible for 22% of 
cancer deaths annually. One factor which may contribute to 
reduced survival is treatment related toxicity. Whether the 
cardiotoxic effect of chemo-radiation may contribute to 
adverse outcome in lung cancer is uncertain. The aim of this 
pilot study is to use cardiac MRI to investigate cardiac muscle 
injury, function and cardiac biomarkers in patients being 
treated for non-small cell lung cancer (NSCLC).  
Materials and Methods: The study plans to recruit 20 
evaluable NSCLC patients. Study assessments are made on 4 
occasions: pre-treatment, during treatment, 6 weeks and 6 
months after treatment initiation. Evaluations include clinical 
assessment, cardiac MRI, ECG and serum cardiac biomarkers. 
